Changeflow GovPing Healthcare & Life Sciences Scabigard Suspension Class II Recall - Product ...
Urgent Enforcement Amended Final

Scabigard Suspension Class II Recall - Product Defect Affecting Efficacy

Favicon for www.gov.uk UK VMD
Filed
Detected
Email

Summary

The UK Veterinary Medicines Directorate (VMD) has issued a Class II recall alert for Scabigard Suspension for Cutaneous Administration (Vm 42058/5173 and Vm 60021/3020) manufactured by Zoetis. The affected batches may fail to demonstrate expected signs of 'take' following administration. Nine batch numbers are affected, manufactured between June 2024 and January 2025, with expiry dates through December 2026. Wholesalers and veterinarians are required to immediately review inventory and quarantine affected products.

What changed

The VMD has announced a Class II recall for Scabigard Suspension for Cutaneous Administration, a veterinary pharmaceutical product. The recall applies to nine specific batch numbers manufactured by Zoetis between June 2024 and January 2025. The product defect means affected batches may not demonstrate the expected therapeutic response ('take') following administration.

Wholesalers and veterinarians must immediately review their inventory, identify affected batches, and quarantine the product. End users who have purchased the product should return it to the veterinary practice from which it was obtained. Zoetis is directly contacting the supply chain to facilitate returns and replacements.

What to do next

  1. Quarantine affected product batches immediately
  2. Contact Zoetis at 0345 300 8034 for return instructions
  3. Return affected product to veterinary practice

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

News story

Scabigard Suspension for Cutaneous Administration - product defect recall alert

Product defect recall alert for Scabigard Suspension for Cutaneous Administration - Vm 42058/5173 and Vm 60021/3020 by Zoetis Belgium S.A.

From: Veterinary Medicines Directorate Published 2 April 2026

We wish to inform wholesalers, veterinarians and end users that Zoetis has initiated a Class II recall for Scabigard Suspension for Cutaneous Administration, UK(GB) Vm 42058/5173 by Zoetis UK Limited and UK(NI) Vm 60021/3020 by Zoetis Belgium S.A.

The reason for this recall is that the affected batches may not demonstrate the expected signs of take following administration.

This recall applies to the following batches:

Batch number Date of manufacture Expiry date
7482095A01 June 2024 May 2026
7482095A02 June 2024 May 2026
7482095B01 June 2024 May 2026
7482095B02 June 2024 May 2026
7482095D01 June 2024 May 2026
7482095D02 June 2024 May 2026
7482096A01 August 2024 July 2026
748209701 January 2025 December 2026
748209702 January 2025 December 2026

Zoetis is contacting wholesalers and veterinarians to immediately review inventory and quarantine products subject to this recall.

End users should return any affected product to the veterinary practice from which it was purchased.

For further information regarding this recall, please contact Zoetis on 0345 300 8034 or at customersupportUK@zoetis.com.

Share this page

The following links open in a new tab

Updates to this page

Published 2 April 2026

Get daily alerts for UK VMD

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from VMD.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
VMD
Filed
April 2nd, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Healthcare providers Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Product recall response Market withdrawal Inventory quarantine
Threshold
Affected batches: 7482095A01, 7482095A02, 7482095B01, 7482095B02, 7482095D01, 7482095D02, 7482096A01, 748209701, 748209702
Geographic scope
United Kingdom GB

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Topics
Product Safety Public Health

Get alerts for this source

We'll email you when UK VMD publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!